Cormedix INC Form 4 insider transactions

CorMedix's Chief Legal Officer, Beth Zelnick Kaufman, amended a previous SEC filing to correct the number of shares owned after a transaction.

CorMedix's Chief Legal Officer, Beth Zelnick Kaufman, reported the acquisition of 12,500 shares of common stock and the disposition of 6,044 shares to cover tax obligations.

CorMedix EVP, Chief Commercial Officer Erin Mistry purchased 1,500 shares of company stock at $9.9899 per share on October 31, 2024.

Elizabeth Hurlburt, an EVP at CorMedix Inc., executed multiple stock options and sold a significant number of shares on November 14, 2024.

Joseph Todisco, CEO of CorMedix Inc., disposed of 26,982 shares of common stock on May 10, 2024, to cover tax obligations.

Director Steven W. Lefkowitz reports the acquisition of stock options in CorMedix Inc.

Director Robert A. Stewart reports the acquisition of 30,000 stock options in CorMedix Inc. on March 5, 2024.

Director Myron Kaplan reports acquisition of 30,000 stock options in CorMedix Inc.

Director Janet Dillione reports acquisition of stock options in CorMedix Inc.

Alan W. Dunton, a director of CorMedix Inc., reported the acquisition of 30,000 stock options on March 5, 2024.

Director Gregory Scott Duncan of CorMedix Inc. reports acquiring 30,000 stock options on March 5, 2024.

CorMedix CEO Joseph Todisco recently purchased 13,561 shares of common stock, increasing his direct holdings in the company.